Molecular advances, subgroups and classification of medulloblastoma md pathology 10 marks question answer in a way that I can replicate in exams

Reading File

Finding Sources

Reading File

Finding Sources

Searching PubMed

medulloblastoma molecular subgroups classification

Medulloblastoma – Molecular Advances, Subgroups and Classification

(Pathology – 10 Marks, Exam Format)

1. Introduction (1 mark)

Medulloblastoma is a highly malignant, WHO Grade IV embryonal ("small round blue cell") tumour of the cerebellum, accounting for ~20% of pediatric brain tumours. It arises from the external granular layer/subependymal matrix cells of the cerebellum. Although classically diagnosed by histology, advances in transcriptomic and methylation profiling have shown that "medulloblastoma" is not one disease but a group of biologically distinct tumours — this forms the basis of the current WHO 2016/2021 molecular classification.

2. Historical vs Current Classification (1 mark)

Era	Basis of Classification
Older (pre-2016)	Purely histological: Classic, Desmoplastic/Nodular, Extensive nodularity, Large cell/Anaplastic
WHO 2016 CNS classification	Integrated histological + molecular (layered) diagnosis
WHO 2021 CNS5	Predominantly molecular subgrouping, with histology as a subtype modifier

3. Four Molecular Subgroups (Core Answer – 5 marks)

Genome-wide expression and methylation profiling (Taylor et al., 2012) divided medulloblastoma into 4 principal molecular groups:

Subgroup	Molecular Alterations	Age Group	Location	Histology	Prognosis
WNT-activated	CTNNB1 (β-catenin) mutation, monosomy 6; APC mutation in Turcot syndrome	Children/older children	Cerebellar peduncle/CP angle	Usually classic	Best — >90-95% 5-yr survival
SHH-activated	PTCH1, SMO, SUFU mutations (TP53 wild-type); TP53 mutation with GLI2/MYCN/SHH amplification (TP53-mutant)	Bimodal: infants and adults (rare in children 3-16 yrs)	Cerebellar hemispheres	Often desmoplastic/nodular; extensive nodularity in infants	Variable – good if TP53 wild-type; very poor if TP53-mutant
Group 3 (non-WNT/non-SHH)	MYC amplification/overexpression	Infants & young children	Fourth ventricle/midline	Large cell/anaplastic often	Worst prognosis, especially with MYC amplification + metastasis
Group 4 (non-WNT/non-SHH)	Isochromosome 17q (most common cytogenetic abnormality overall); KDM6A mutations	Wide age range (children/adolescents), M>F	Fourth ventricle	Classic	Intermediate prognosis

Key associated pathways/genes to remember:

WNT pathway → APC/β-catenin (also linked to Turcot syndrome)
SHH pathway → PTCH1 (also linked to Gorlin/NBCC syndrome) – SMO – SUFU – GLI2
TP53 status subclassifies SHH tumours into wild-type (better) vs mutant (worse)
MYC/MYCN amplification → aggressive, Group 3, anaplastic morphology
Isochromosome 17q → hallmark of Group 4

4. WHO 2016/2021 Diagnostic Categories (1 mark)

Medulloblastoma, WNT-activated
Medulloblastoma, SHH-activated and TP53-wildtype
Medulloblastoma, SHH-activated and TP53-mutant
Medulloblastoma, non-WNT/non-SHH (provisionally Group 3 and Group 4)
Medulloblastoma, histologically defined (NOS) — used when molecular testing is unavailable
- Classic
- Desmoplastic/nodular
- Medulloblastoma with extensive nodularity
- Large cell/anaplastic

(WHO CNS5, 2021 further refines Group 3/4 tumours using methylation-based subtyping, but Group 3/4 remain "provisional" entities pending further stratification.)

5. Clinical Significance of Molecular Classification (1 mark)

Risk stratification: guides intensity of chemo/radiotherapy (e.g., reduced-therapy protocols being trialed for WNT tumours given excellent prognosis; intensified therapy for MYC-amplified Group 3/TP53-mutant SHH tumours).
Prognostic biomarker: molecular subgroup is now a stronger prognostic indicator than histology alone.
Diagnostic tool: immunohistochemistry surrogates (β-catenin nuclear positivity for WNT, GAB1/YAP1 for SHH, p53 for TP53-mutant) and methylation array profiling are used when full genomic testing is unavailable.
Targeted therapy potential: SMO inhibitors (e.g., vismodegib) under trial for SHH-activated tumours.

6. Diagram to Draw in Exam

Draw a simple 4-box flow:

        MEDULLOBLASTOMA
              |
   -----------------------------------------
   |          |               |            |
  WNT        SHH            Group 3      Group 4
(CTNNB1,   (PTCH1/SMO/     (MYC amp)    (iso17q)
 mono6)     SUFU ± TP53)
Best px    Variable px    Worst px     Intermediate

7. Conclusion (1 mark)

Medulloblastoma has evolved from a purely histological diagnosis to an integrated histomolecular entity under WHO classification. The four molecular subgroups — WNT, SHH, Group 3, and Group 4 — differ in their genetic drivers, patient demographics, and prognosis, and this molecular stratification now directly informs risk-adapted therapy, making it essential knowledge for both pathology and clinical oncology.

Sources: Robbins & Kumar Basic Pathology, p. 862-863; Bradley and Daroff's Neurology in Clinical Practice, p. 1526-1527 (Table 72.3); Harrison's Principles of Internal Medicine 22E.

Note on recent literature: Current systematic reviews (2024-2025, e.g., PMID 40938375 on MRI-based AI prediction of subtypes, PMID 39467891 on radiomics for subtyping) do not change the core WHO molecular subgrouping described above — they focus on non-invasive imaging/AI methods to predict subgroup preoperatively, which is a useful "recent advances" line to add for extra marks if the question specifically asks for cutting-edge developments.

This is a shared conversation. Sign in to Orris to start your own chat.